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Abstract 
Currently, application of new technological solutions for the implementation of strategies for improving influenza 
vaccines are up to date and modern. In this study, we present data obtained in the evaluation of the safety and 
immunogenicity of the new Russian (national) split seasonal inactivated influenza vaccine ULTRIKS in comparison 
with a commercial vaccine VAXIGRIP in various age groups. 
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1. Main text  
Vaccination is the primary strategy for prevention and control of influenza. In Russia, for the specific prevention 
of influenza are mainly used in inactivated vaccines, and to a lesser extent the live influenza vaccine. The principal 
drugs of modern influenza immunization in Russia are inactivated polymer-subunit vaccines, which include surface 
antigens (hemagglutinin and neuraminidase) of influenza virus A (H1N1), A (H3N2), B, and high molecular 
immune adjuvant azoksimera bromide1. Maximum preventive effect of these drugs is achieved with full compliance 
of their composition of strains with circulating current epidemic season of influenza viruses. Get the prophylactic 
effect in cases of incomplete coincidence of strains, possibly with the application of an inactivated vaccine the split 
type having in its composition, and surface and internal proteins of influenza viruses. Until recently, the Russian 
pharmaceutical market were only foreign split vaccine type. The use of new technological solutions makes such 
vaccines to date and modern2. Deficiency of these drugs eliminates developed in 2005 influenza inactivated split 
vaccine ULTRIKS in which surface and internal antigens going into virus particles, giving an optimal immune 
response3. 
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Objective: To assess the safety and immunogenicity of a new domestic split seasonal inactivated influenza 
vaccine ULTRIKS in comparison with the commercial vaccine VAXIGRIP in different age groups). 
1.1. Structure 
Clinical trials conducted in the flu season 2007-2011. The total number of observed was 1 236 people. Inclusion 
of volunteers in the study was determined by the following criteria: for those aged 18 to 60 years - clinical health, 
written informed consent required by the immune status of the magnitude of antibody titer ≤ 1:40 HAI according 
to the corresponding antigen of influenza A (H1N1) and (H3N2 ) and Type B; for persons aged 60 years and 
older-stable parameters of the basic functions of life, written informed consent, the ability to understand and 
comply with planned study procedures required by the immune status of the magnitude of the antibody titer ≤ 
1:20 HI assay according to the corresponding antigen of influenza A (H1N1) and (H3N2) and B; for children 
aged 6 to 18 years clinical health, the legal representative of the child's ability to understand and comply with 
planned study procedures, and written informed consent of the legal representative of the child, the immune 
status of the required quantity of antibody titer ≤ 1:40 HAI according to the corresponding antigen of influenza A 
viruses (H1N1), (H3N2) and B. The exclusion criteria for persons of all age groups were: allergic reactions to 
chicken protein or preceding flu-like vaccination, asthma, chronic lung disease, chronic rhinitis, 
immunodeficiency (primary), immunosuppression, acute infectious and non-communicable diseases, 
exacerbation of chronic diseases, a history of leukemia, cancer or a positive response to HIV, hepatitis B and C, 
receiving immunoglobulin preparations or blood transfusion in the last three months prior to the study, previous 
reaction to a flu vaccine. Additional exclusion criteria for persons in age group of 18 to 60 years were pregnancy 
or lactation, for persons aged 60 years and older from dementia or dementia therapy. 
Studied drugs: ULTRIKS - vaccine for the prevention of influenza inactivated split, single solution for 
intramuscular injection. HA content in the preparation of 45 mcg / dose - 15 mcg hemagglutinin subtypes of 
influenza virus strains A (H1N1), (H3N2) and B. Produced using the original conditions virion influenza viruses 
destruction detergent β-octyl glucoside, followed by self-assembly of surface and internal antigens in the virus-
like particles that are close to the natural shape of viruses. Manufacturer: Fort Ltd, Russia LSR-001419/08 dated 
11.03.2008. VAXIGRIP - a vaccine for the prevention of influenza inactivated split for a single intramuscular or 
subcutaneous administration of Certificate of registration № 014493/01-2002. Form release: vial. Manufacturer: 
"Sanofi Pasteur", France. 
In the studied seasons in the study included the following vaccine strains recommended by WHO: 2006 2007g.g.: 
A/New Caledonia/20/99 (H1N1)-like; A/Wisconsin/67/2005 (H3N2)-like; In / Malaysiya/2506/2004-like; 2007 
2008g.g.: A /Solomon Islands/3/2006 (H1N1)-like; A/Wisconsin/67/2005 (H3N2)-like; B/Malaysiya/2506/2004 -
like: 2008 - 2009yy: A/Brisbane/59/2007 (H1N1)-like; A/Brisbane/10/2007 (H3N2)-like; B/Florida/4/2006-like; 
2010 2011. : A/California/7/2009 (H1N1)-like; A/Perth/16/2009 (H3N2)-like; B/Brisbane/60/2008-like. 
Immunogenicity of influenza vaccine immunogenicity was evaluated according to the criteria for adults, 
approved by the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (MC 
3.3.2.1758-03 2003) criteria for immunogenicity of influenza vaccines for human Committee requirements for 
Proprietary Medicinal Products (CPMP EMEA SRMR/EWR/1045/01) 
In 2007, by supervision there were 100 people, clinically healthy volunteers aged 18 to 60 years (mean age 33,3 
± 0,04 years) randomized in two groups of 50 people each, vaccinated intramuscularly once vaccine ULTRIKS 
and the comparator VAXIGRIP with antigenic load 45 mcg hemagglutinin each. Observation of the volunteers 
continued for 21 days. Rating reactogenicity properties of preparations indicated an absence of local reaction to 
their introduction. Systemic reactions were mild severity. In the group vaccinated with the preparation ULTRIKS 
45 mcg, marked 12% of these reactions (95% ID 2,1-16,2), in the group vaccinated VAXIGRIP - 8% (95% ID 
2,2-18,8) (p> 0.05) (Table 1). Established safety of used vaccines. Performance Evaluation of clinical and 
biochemical blood tests and clinical analysis of urine in the dynamics (before vaccination, at 7 and 21 days of 
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observation) revealed no significant changes observed in all these indicators remained within the normal range 
(Table 2). 
Thus, there was no evidence of side effects from the use of vaccines in the regulated standard hematological, 
biochemical tests. Fluctuations content of IgE in sera were minor and remained within the normal range after 
administration of the vaccine. The findings suggest that the absence of allergenic effects on the organism studied 
vaccine in healthy adult volunteers. The immunogenic activity of the vaccines were evaluated during the study 
paired sera observed in HI assay taken before and 21 days after immunization4.  
Individuals vaccinated ULTRIKS 45 mcg, seroconversion virus A (H1N1), A (H3N2) and B amounted to 94.0% 
(95% ID: 83,5-98,7), 86.0% (95% ID: 73,3-94,9) and 90.0% (95% ID: 78,2-96,7). Seroconversion factor 
amounted to 19.4, 9.4 and 6.9. Seroprotection rate was equal to 86.0% (95% ID: 73,3-94,9), 90.0% (95% ID 
78,2-96,7) and 78.0% (95% ID: 64.0 - 85.0), respectively. Seroconversion in vaccinated drug VAXIGRIP virus A 
(H1N1), A (H3N2) and B was 98.0% (95% ID: 89,4-99,9), 94.0% (95% ID: 83,5-98 7) and 88.0% (95% ID: 
75,7-95,5) accordingly seroprotection rate - 100.0, 94.0% (95% ID: 83,5-98,7) and 86.0% (95% ID: 73,3-94,9), 
seroconversion factor - 26.7, 9.7 and 14.7 accordingly (Table 3). 
Thus, it was shown that the vaccine ULTRIKS 45 mcg criteria for immunogenicity not inferior to comparator 
drugs VAXIGRIP vaccine and fully complies with the requirements of the inactivated influenza seasonal 
vaccines by the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (MC 
3.3.2.1758-03) and the Committee of proprietary Medicinal Products (CPMP EMEA SRMR/EWR/1045/01). The 
next phase of research was to evaluate the possibility of using vaccines ULTRIKS 45 mcg for specific prevention 
of influenza in the elderly aged 60 years and older. Currently, the importance of immunization of older people is 
recognized in all countries where influenza vaccination is carried out, but data on its effectiveness are 
contradictory and require further study5,6. Qualitatively the vaccination can significantly reduce the burden of 
disease and avoid complications in the elderly7,8. The total number was observed 40 people randomized to 2 - 
groups of 20 persons each: Group 1 vaccinated drug ULTRIKS 45 mg, group 2 received the comparator drug 
VAXIGRIP. The average age of volunteers was 67.7 years +3.1 years. Evaluation properties reactogenic vaccine 
showed the absence of local and systemic reactions in human volunteers during the first 20 minutes after 
vaccination. In the next 7 days registered local reaction refers to a reaction of mild to moderate severity. In the 
group vaccinated ULTRIKS 45 mcg total number of local reactions was 5 cases - 25% (95% ID: 11,2-46,9), and 
among volunteers vaccinated VAXIGRIP 3 cases - 15% (95% ID: 5,2-36 , 0). Number of weak systemic 
reactions observed in the same number of observed in both groups - 3. In the analysis of drug safety laboratory 
results indicated that the average general and biochemical blood tests and urinalysis observed in both groups, at 
different stages of the survey endured minor changes, while remaining within the normal range. The initial level 
of total Ig E at all observed prior to vaccination and on the 7th day after vaccination remained within normal 
parameters, indicating the absence of allergenic effect studied vaccines.  
In vaccinated volunteers by ULTRIKS 45, four time seroconversion to influenza A (H1N1) detected in 80.0% 
(95% ID: 58,4-91,9), the multiplicity of growth was 9.5 antibodies . Seroprotection rate was 70.0% (95% ID: 
48,1-85,5). By the virus A (H3N2), the figures were 85.0% (95% CI 64,0-94,8), 12.1 % and 90.0% (95 % CI 
69,9-97,2), the virus type B - 65.0 % (95 % ID: 76,4-99,1), 28.3 and 50.0 % (95 % ID: 29,9-70,1), respectively. 
Seroconversion to the virus A (H1N1), A (H3N2) and B was 95.0% (95% ID: 76,4-99,1), 90.0% (95% ID: 69,9-
97,2) and 80.0% (95% ID: 58,4-91,9 ), seroprotection rate - 95.0% (95% ID: 76,4-99,1), 90.0% (95% ID: 69,9-97 
2 ) and 80.0 % (95 % ID: 58,4-91,9), seroconversion factor - 21.9, 12.6 and 7.5 (Table 4). 
The results showed that the immunogenicity of the vaccine ULTRIKS with antigenic load 45 mcg hemagglutinin 
in the age group over 60 years to meet the criteria CPMP criteria 2 seroconversion factor and level of 
seroconversion , and the level of seroprotection against influenza B virus - on the threshold recommended . The 
results obtained led to the recommendation for registration in Russia Flu vaccine inactivated split , solution for 
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intramuscular injection ULTRIKS with content 45 mcg hemagglutinin (15 mcg serotype H1N1, H3N2 serotype 
15 mcg and 15 mcg of serotype B). 
The next step was to study the safety and immunogenicity of the drug ULTRIKS 45 children aged 12 to 18 years 
with a subsequent decrease to 6 years of age. Since children are the least protected against drift variants of 
influenza virus within the same serotype, they belong to the "double jeopardy", firstly, because of the increased 
risk of infection for both epidemiologically active contingent, and, secondly, in connection with an increased risk 
of adverse effects of influenza because of the immaturity of the immune system. Establishment of new influenza 
vaccines lets you expand of specific protection, reduce the incidence of children with influenza and, as a 
consequence, the number of complications requiring antibiotics, in particular, as well as infant mortality9. The 
first study involved 36 healthy children aged 12 to 18 years who were randomized to 2 groups. Vaccine 
ULTRIKS 45 mcg got 20 children (mean age 15.9 +1.2 years). 16 children received the vaccine VAXIGRIP 
(mean age 15.7 +1.1 years). Evaluation reactogenicity of vaccines showed that 20 minutes after vaccination local 
and general reactions have been recorded in any of the observed in both groups were well tolerated vaccines. The 
safety assessment of vaccines according to laboratory parameters general and biochemical blood tests for 
dynamic observation testified that these indicators endured minor changes and remained within the normal range. 
In analysis of urine marked slight deviations from the normal values: as in the original samples in 4 (20.0%, 95% 
ID: 8,1-41,6) observed in the drug group ULTRIKS 45 mcg and in 4 (25.5%, 95% ID: 10,2-49,5) in group 
VAXIGRIP and during follow 21 days after vaccination, 20.0%(95% ID: 8,1-41,6) in the vaccinated group and 
ULTRIKS 45 mcg 37.5 % (95% ID: 18,5-61,4) grafted VAXIGRIP. The others of the observed performance of 
urinalysis were within normal limits at all stages of the study. Normal baseline IgE was observed in only 5 people 
in the vaccinated group ULTRIKS 45 mcg drug (25.0%, 95% ID: 11,2-46,9) and the same amount of 5 people in 
the vaccinated group VAXIGRIP (31.25% 95% ID: 14,2-55,6). For most children, 45.0% (95% ID: 25,8-65,8) in 
group ULTRIKS 45 mcg and 62.5% (95% ID: 38,6-81,5) in group VAXIGRIP indicators IgE prior to 
vaccination were below normal values at 30.0% (95% ID: 14,5-51,9) and 6.25% (95% ID: 1,1-28,3), 
respectively, these figures were much higher than initially normal values which coincides with the general trend 
in the population. Importantly, vaccination IgE indicators remained at the initial value, i.e. vaccine does not 
possess allergenic action. The observations have revealed sufficient immunogenic activity of the drug ULTRIKS 
45 mcg: seroconversion in 70% (95% ID: 48,1-85,5) to influenza A(H1N1), 50% (95% ID: 29,9-70,1) to 
influenza virus A(H3N2) and 70% (95% ID: 48,1-85,5) to influenza B; seroprotection rate of 90% (95% ID: 
69,9-97,2) to influenza A(H1N1) , 80% (95% ID: 58,4-91,9) to influenza A(H3N2) and 85% (95% ID: 64,0-94,8) 
influenza virus B, the multiplicity of growth of antibody titers accordingly 6.5, 2.7, 4.0, which is comparable to 
the reference drug VAXIGRIP immunogenicity to influenza serotype H1N1, H3N2 and type B (Table 5). 
Thus, this study showed that the vaccine is safe ULTRIKS 45 mcg, has expressed immunogenic activity against 
influenza viruses A and B, when used in the age group of 12 to 18 years. 
In the next study in 2010-2011 attended by 42 healthy children aged 6 to 12 years were randomly sampling 
distribution in 2 randomized groups: 21 children vaccinated drug ULTRIKS 45 mcg (mean age 8.3 0.5 years), 21 
children vaccinated drug VAXIGRIP (mean age-7.9 0.6 years). Dynamic observation of general indicators and 
biochemistry blood tests, clinical analysis of urine showed no significant changes. All of these indicators were 
within normal limits. Significant differences between the study groups of children vaccinated and ULTRIKS 45 
mcg VAXIGRIP not noted (p> 0,05). In this age group initially high levels of total IgE marked before 
vaccination in the main group 55% (95% ID: 34,2-74,2) observed, and in 60% (95% ID: 38,7-78,1) in the control 
group. In the post-vaccination period there was a significant reduction in the average level of total IgE was 1.8 
times after immunization ULTRIKS 45 mcg and 1.4 times after immunization VAXIGRIP (p <0,05), which 
confirms the absence of allergenic effect applied drugs. Evaluation of immunogenic activity of vaccines showed: 
seroconversion in 61.9% (95% ID: 40,9-79,2) to influenza A (H1N1), 81% (95% ID: 60,0-92,3) influenza virus a 
(H3N2), and 42.9% (95% ID: 24,5-63,5) influenza virus, the level of seroprotection 95.2% (95% ID: 7,3-99,2) to 
influenza a (H1N1), 90.5% (95% ID: 71,1-97,3) to influenza a (H3N2) and 42.9% (95% ID: 24,5-63,5) influenza 
virus B, and so same multiplicity increase in antibody titers accordingly 4.0, 5.3, 2.5. In the vaccinated group 
28   M.К. Erofeeva et al. /  Procedia in Vaccinology  8 ( 2014 )  24 – 33 
VAXIGRIP seroconversion to influenza A (H1N1) was equal to 71.4% (95% ID: 50,0-86,2), influenza virus A 
(H3N2), 47.6% (95% ID: 28, 3-67,6) and influenza virus in 42.9% (95% ID: 24,5-63,5) seroprotection rate of 
95.2% (95% ID: 77,3-99,2) to A (H1N1 ), 90% (95% ID:I 71,1-97,3) to A (H3N2) and 40% (95% ID: 20,8-59,1) 
influenza virus, the multiplicity of growth of antibodies 6.3 to A (H1N1), 2.7 to A (H3N2) and 2.6 to B (table 6). 
Study has shown that the results of immunogenicity VAXIGRIP comparable with the results obtained by 
immunization ULTRIKS 45 mcg. Thus, a vaccine ULTRIKS 45 mcg of children 6 to 12 years, safety, well 
tolerated and has a sufficient immunogenic activity against influenza virus type A. 
All of the volunteers were under the supervision had a history of clinically significant allergic reactions, but 
initially had excess levels of IgE in the age group 18 to 60 years from 14.0% to 28.0% of cases. After 
vaccination, IgE levels tended to increase in 32.0% -44.0% of cases. These changes occurred among vaccinated 
ULTRIKS 45, and in the vaccinated group VAXIGRIP. In the older age group, the mean values of IgE before 
vaccination were within normal values. In the group of children, aged 6 to 18 years of normal IgE values before 
vaccination identified only 25.0% and 31.3% observed, respectively. After vaccination rate IgE remained at the 
initial level. In children, the youngest age group (6 - 12 years) initially high IgE levels set at 55.0% of 60% of 
children. During the observation 21 days after the vaccination was statistically significant reduction in the level 
of IgE in 1.4 1.8. The reason for the increased content of total IgE in otherwise healthy children, probably due to 
the influence of adverse environmental factors that contribute to the development of disorders in immunological 
reactivity10,11. Us in the course of studies have shown that the use of drugs and ULTRIKS. VAXIGRIP not 
accompanied by increased production of IgE and the occurrence of allergic component, but rather its decline not 
only in individuals with normal levels of these antibodies, but also in individuals with latent sensitization. This is 
confirmed in the literature. Found that both live and inactivated vaccines are almost resistant to stimulate and 
increase the level of IgE production of specific IgE-antibodies12,13,14. 
Additional study of the immunogenicity of the vaccine ULTRIKS 45 micrograms of 100 vaccinated volunteers 
showed that the four-fold rise in antibody titers to influenza A(H1N1) detected in 77.0% (95% CI 67,8-84,2), 
multiple antibodies growth was 7 , 0. Seroprotection rate was 84.0% (95% ID:. 75,6-89,9). To virus A(H3N2), 
the figures were 61.0%(95% ID: 51,2-70,0), 4.0 and 77.0% (95% ID: 67,8-84,2) virus type C - 71.0% 67.8 -
84.2%), 4.7 and 61.0% (95% ID: 51,2-70,0), respectively. Study duration conservation postvaccination humoral 
immunity showed that after 90 and 180 days after a single vaccination with ULTRIKS 45 antibody titers in 
vaccinated saved at a high enough level. The number of persons with up to 4x increase in antibody titer after 6 
months to the virus A(H1N1) was 68.1% instead of 77.0% to the virus A (H3N2) 51.6% instead of 61.0% and to 
the virus in this figure was equal to 62.6% instead of 71.0%. Multiplicity increase in antibody titers also 
decreased slightly to the virus A (H1N1) from 7.0 to 6.1, the virus A (H3N2) - from 4.0 to 3.1 and in 4.6 to 3.6. 
The number of individuals with protective antibody titers was 81.3, 61.5 and 47.3 and 61.0 instead 84,0,77,0 
virus A (H1N1), A (H3N2) and B (Table 7). 
Conclusions.  
1. Areactogenecity established and safety of the vaccine ULTRIKS in all age groups from 6 to 60 years of age 
and older in clinical, not a statistically significant change in the results of clinical and laboratory studies. 
2. Defined immunogenic activity study of the vaccine in different age groups, corresponding to the requirements 
of the Federal Service for Supervision of Consumer Rights Protection and Human Welfare (MC 3.3.2.1758-03) 
and international requirements Committee Proprietary Medicinal Products (CPMP EMEA, CPMP/EWP/1045 / 
01) for the quad conversion observed in the serum of persons: influenza virus a (H1N1) - up 94.0% to a (H3N2) - 
up to 90%, to B - to 90.0% growth by the multiplicity of antibodies accordingly to 21.9, 12.6, 7.5, accordingly on 
the level of seroprotection rate to 95.0%, 90.0% and 78.0%. 
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3. Is shown duration of preservation of humoral immunity in vaccinated ULTRIKS 45 mcg for 3 and 6 months 
after vaccination. 
A vaccine for the prevention of influenza ULTRIKS among all age groups has allowed Russia to expand the list 
of domestic products for specific disease prevention, receive additional doses of the vaccine during the pandemic 
and avoid ethical issues associated with their distribution 15. 
1.2. Tables  
Table 1. Local and systemic reactions associated with vaccination and drugs ULTRIKS 45 VAXIGRIP 
volunteers 18 - 60 years 
Immunization reactions ULTRIKS 45 mcg 
n=50 
VAXIGRIP 
n=50 
Absolute quantity of local 
reactions/% 
(95% CL) 
Minor no 3/6,0 (2,1-16,2) 
Medium no no 
Severe no no 
Total no 3/6,0 (2,1-16,2) 
Absolute quantity of systemic 
reactions /% 
(95% CL) 
Minor 6/12,0 (2,1-16,2) 4/8,0 (2,1-16,2) 
Medium no no 
Severe no no 
Total 6/12,0 (2,1-16,2) 4/8,0 (2,1-16,2) 
 
Table 2. Dynamics of indicators of biochemical blood analysis in the study of vaccine safety ULTRIKS 45 in 
comparison with the vaccine VAXIGRIP volunteers 18 - 60 years 
Indicators 
ULTRIKS 45мкг n=50 
(M±m) 
VAXIGRIP n=50 
(M±m) 
Day 1 Day 7 Day 21 Day 1 Day 7 Day 21 
ALT (U/l) 25,2±3,3 25,5±3,4 24,0±4,5 21,3±4,1 20,8±3,6 21,5±2,3 
AST (U/l) 24,7±3,0 26,9±4,0 23,7±3,3 23,1±4,0 23,2±2,8 25,0±3,1 
Total Bilirubin 
(mcmol/l) 15,7±1,1 14,2±1,1 15,2±1,1 12,6±0,9 13,4±1,3 13,4±0,7 
Creatinine 
(mcmol/l) 87,4±1,4 86,8±1,2 86,2±1,6 81,8±1,2 83,7±1,4 81,7±1,6 
ALP (U/l) 71,1±2,9 70,6±2,9 69,5±3,4 68,5±3,6 67,6±3,1 66,0±3,3 
Urea (mol/l) 4,8±0,2 5,1±0,2 4,8±0,2 5,0±0,1 5,0±0,2 5,0±0,2 
Total Protein (g/l) 72,7±2,4 74,2±0,4 73,9±0,5 72,9±0,7 72,9±1,0 73,1±0,8 
CRP (mg/l) 4,2±0,4 4,2±0,5 4,5±1,2 3,8±0,3 4,0±0,9 4,3±0,6 
Glucose (mol/l) 5,3±0,1 5,4±0,1 5,2±0,2 5,8±0,2 5,3±0,2 5,4±0,3 
n - the number of volunteers 
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Table 3 - The antigenic activity of influenza vaccine and vaccine ULTRIKS 45 mcg comparison VAXIGRIP 
Preparation Antigen 
Absolute 
Level of 
Seroconvesion
/%  
(95% CL) 
Geometric Mean 
Antibody Titres Seroconversion 
Factor (1-2 sera) 
(95% CL) 
Absolute 
Seroprotection 
Rate/% (95% 
CL) Absolute Qty 
(95% CL) 
Day 1 
(95% CL) 
Day 7 
(95% CL) 
ULTRIKS-
45 mcg 
n=50 
A/New 
Caledonia/20/99 
(H1N1) 
47/94,0 
(83,5-98,7) 
11,3 
(9,2-13,9) 
220,1 
(147,8-327,8) 
19,4 
(13,6-27,7) 
86,0 
(73,3-94,2) 
A/Wisconsin/67/200
5 
(H3N2) 
45/90,0 
(78,2-96,7) 
15,8 
(12,7-19,7) 
149,3 
(106,2-209,9) 
9,4 
(6,9-12,9) 
90,0 
(78,2-96,7) 
B/Malaysia/2506/20
04 
43/86,0 
(73,3-94,2) 
8,2 
(7,2-9,5) 
56,6 
(42,2-75,8) 
6,9 
(5,4-8,8) 
78,0  
(64,0-88,5) 
VAXIGRIP 
n=50 
A/New 
Caledonia/20/99(H1
N1) 
49/98,0 
(89,4-99,9) 
13,7 
(10,9-17,4) 
367,6 
(264,8-510,4) 
26,7 
(19,4-30,2) 100,0 
A/Wisconsin/67/200
5 
(H3N2) 
47/94,0 
(83,5-98,7) 
13,9 
(10,9-17,8) 
135,5 
(104,5-175,7) 
9,7 
(7,0-13,5) 
94,0 
(83,5-98,7) 
B/Malaysia/2506/20
04 
44/88,0 
(75,7-95,5) 
8,2 
(7,1-9,6) 
121,2 
(80,2-183,4) 
14,7 
(10,1-21,4) 
86,0 
(73,3-94,2) 
n - the number of volunteers 
 
Table 4. Antigenic activity of influenza vaccines ULTRIKS 45 mcg and VAXIGRIP volunteers over 60 years 
Antigen 
Absolute Level of 
Seroconvesion/% 
(95% CL) 
Geometric Mean Antibody 
Titres Seroconversion 
Factor (1-2 sera) 
(95% CL) 
Absolute 
Seroprotection 
Rate/% (95% CL) Day 1 (95% CL) 
Day 21 
(95% CL) 
ULTRIKS 
n=20 
A/Solomon 
Islands/03/06 (H1N1) 
16/80,0 
(58,4-91,9) 
6,4 
(5,1-7,9) 
60,6 
(33,6-109,2) 
9,5 
 
14/70,0 
(48,1-85,5) 
A/Wisconsin/67/05 
(H3N2) 
17/85,0 
(64,0-94,8) 
10,0 
(6,9-14,4) 
121,1 
(69,1-212,2) 
12,1 
 
18/90,0 
(69,9-97,2) 
B/Malaysia/2504/04 
13/65,0 
(43,3-81,9) 
7,12 
(5,2-9,6) 
34,8 
(18,6-65,2) 
4,9 
 
10/50,0 
(29,9-70,1) 
VAXIGRIP 
n=20 
A/Solomon 
Islands/03/06 (H1N1) 
19/95,0 
(76,4-99,1) 
7,6 
(5,6-10,3) 
165,6 
(90,7-284,6) 
21,1 
 
19/95,0 
(76,4-99,1) 
A/Wisconsin/67/05 
(H3N2) 
18/90,0 
(69,9-97,2) 
10,3 
(7,6-14,1) 
125,3 
(7,6-14,1) 
12,1 
 
18/90,0 
(69,9-97,2) 
B/Malaysia/2504/04 
16/80,0 
(58,4-91,9) 
9,0 
(5,7-14,3) 
44,3 
(22,4-87,9) 
4,29 
 
16/80,0 
(58,1-91,9) 
n - the number of volunteers 
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Table 5. Antigenic activity of influenza vaccines ULTRIKS 45 mcg and VAXIGRIP in children aged 12 - 18 
years 
Antigen 
Absolute 
number of  
children/% 
Absolute Level of 
Seroconvesion/% 
(95% CL) 
Geometric Mean Antibody 
Titres Seroconversion Factor (1-2 sera) 
(95% CL) 
Absolute 
Seroprotection 
Rate/%  
(95% CL) 
Day 1  
(95% CL) 
Day 2 
(95% CL) 
ULTRIKS 
A/Brisbane/59/07 
(H1N1) 
20 14/70,0 
(48,1-85,5) 
29,3 
(16,7-51,4) 
190,3 
(91,9-394,1) 6,5 
18/90,0 
(69,9-97,2) 
A/Brisbane/10/07 
(H3N2) 
20 10/50,0 
(29,9-70,1) 
31,4 
(17,6-56,0) 
85,7 
(43,7-168,1) 2,7 
16/80,0 
(58,4-91,9) 
B/Florida/04/06 
20 14/70,0 
(48,1-85,5) 
27,3 
(17,4-42,9) 
109,3 
(58,9-202,7) 4,0 
17/85,0 
(64,0-94,8) 
VAXIGRIP 
A/Brisbane/59/07 
(H1N1) 
16 
12/75,0 
(50,5-89,8) 
27,1 
(14,0-52,4) 
380,5 
(185,3-
781,7) 9,1 
15/93,8 
(71,7-98,9) 
A/Brisbane/10/07 
(H3N2) 
16 11/68,8 
(44,4-85,8) 
20,0 
(11,9-33,7) 
103,7 
(54,4-197,8) 5,2 
14/87,5 
(64,0-96,5) 
B/Florida /04/06 
16 13/81,3 
(57,0-93,4) 
16,8 
(9,7-29,1) 
153,2 
(99,0-237,0) 9,1 
15/93,8 
(71,7-98,9) 
 
Table 6. The immunogenic activity of influenza vaccines ULTRIKS 45 mcg and VAXIGRIP in children aged 6-
12 years 
Antigen 
Absolute 
number of  
children/% 
Absolute Level of 
Seroconvesion/% 
(95% CL) 
Geometric Mean Antibody 
Titres Seroconversion Factor (1-2 sera) 
(95% CL) 
Absolute 
Seroprotectio
n Rate/% 
(95% CL) 
1st test 
(95% CL) 
2nd test 
(95% CL) 
ULTRIKS 
A/California/07/0
9 (H1N1) 
21 13/61,9 
(40,9-79,2) 
36,2 
(23,1-56,7) 
154,6 
(110,3-216,3) 4,0 
20/95,2 
(7,3-99,2) 
A/Wisconsin/ 
15/09 (H3N2) 
21 17/81,0 
(60,0-92,3) 
22,8 
(15,4-33,8) 
119,4 
(81,5-174,9) 5,2 
19/90,5 
(71,1-97,3) 
B/Brisbane/33/08 21 9/42,9 (24,5-63,5) 
10,0 
(7,3-13,3) 
22,8 
(17,0-30,6) 2,3 
9/42,9 
(24,5-63,5) 
VAXIGRIP 
A/California/07/0
9 (H1N1) 
21 15/71,4 
(50,0-86,2) 
25,2 
(13,9-45,5) 
165,2 
(107,6-253,6) 6,6 
20/95,2 
(77,3-99,2) 
A/Wisconsin/ 
15/09 (H3N2) 
21 10/47,6 
(28,3-67,6) 
32,8 
(23,2-46,4) 
91,2 
(66,9-124,2) 2,8 
19/90,5 
(71,1-97,3) 
B/Brisbane/33/08 21 9/42,9 (24,5-63,5) 
8,5 
(5,4-13,4) 
20,6 
(15,7-27,1) 2,4 
8/40,0 
(20,8-59,1) 
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Table 7. Antigenic activity of vaccine ULTRIKS in 2007-2008 epidemic season. in St. Petersburg (the data of 
HAI) 
Antigen Day of Evaluation 
Absolute Level of 
Seroconvesion/% 
(95% CL) 
Absolute 
Geometric Mean 
Antibody Titres 
(95% CL) 
Seroconversion 
Factor (1-2 sera) 
(95% CL) 
Absolute 
Seroprotection 
Rate/% (95% CL) 
A/Solomon 
Islands /03/06 
(H1N1) 
Before 
immunization 
n=100 
- 11,1 (9,2-13,4) - 
- 
incl. s/n n=84 - 7,9 (7,1-8,9) - - 
Day 21 n=100 77/77,0 (67,8-84,2) 77,8 (63,1-95,9) 7,0 84/84,0 (75,6-
89 9)Incl. s/n n=84 69/82,1 (72,6-88,9) 68,7 (54,7-86,9) 8,7 68/81,0 (71,3-
87 9)Day 90 n=95 64/67,4 (57,4-76,0) 64,3 (51,2-80,7) 5,8 69/72,6 (62,9-
80 6)Incl. s/n n=81 60/74,1 (63,6-82,4) 57,8 (44,9-74,4) 7,3 55/67,9 (57,1-
77 1)Day 180 n=91 62/68,1 (58,0-76,8) 67,1 (53,7-83,9) 6,1 74/81,3 (72,1-
88 0)Incl. s/n n=75 58/77,3 (66,7-85,3) 61,2 (47,2-79,3) 7,7 58/77,3 (66,7-
85 3)A/Wisconsin/67/
05 (H3N2) 
Before 
immunization 
n=100 
- 12,0 (9,9-14,4) - 
- 
Incl. s/n n=84 - 8,7 (7,8-9,7) - - 
Day 21 n=100 61/61,0 (51,2-70,0) 48,2 (39,6-58,7) 4,0 77/77,00 (67,8-
84 2)Incl. s/n n=84 58/69,1 (58,5-77,9) 40,3 (32,9-49,4) 4,6 61/72,6 (62,3-
81 0)Day 90 n=95 46/48,4 (38,6-58,3) 38,9 (31,6-47,8) 3,2 58/61,1 (51,0-
70 1)Incl. s/n n=80 44/55,0 (44,1-65,4) 31,9 (26,0-39,3) 3,7 43/53,8 (42,9-
64 3)Day 180  n=91 47/51,6 (41,5-61,6) 37,6 (30,7-46,1) 3,1 56/61,5 (51,3-
70 9)Incl. s/n n=78 45/57,7 (46,6-68,0) 31,8 (26,0-38,8) 3,7 43/55,1 (44,1-
65 7)B/Malaysia 
/2504/04 
Before 
immunization 
n=100 
- 8,2 (6,9-9,7) - 
- 
Incl. s/n n=91 - 6,5 (6,0-7,1) - - 
Day 21/ Before 
i i i
71/71,0 (61,5-79,0) 37,3 (30,9-45,4) 4,7 61/61,00 (51,2-
)Incl. s/n n=91 69/75,8 (66,1-83,5) 32,6 (27,0-39,4) 5,0 52/57,1 (46,9-
)Day 90/ Before 
i i i
56/58,9 (48,9-68,3) 30,5 (25,2-37,1) 3,7 45/47,4 (37,6-
3)Incl. s/n n=86 54/62,8 (52,2-72,3) 26,7 (22,2-32,2) 4,1 36/41,9 (32,0-
)Day 180/ Before 
i i ti
57/62,6 (52,4-71,9) 29,5 (24,8-35,1) 3,6 43/47,3 (37,3-
)Incl. s/n n=83 55/66,2 (55,6-75,5) 26,1 (22,2-30,7) 4,0 35/42,2 (32,1-
2 9)n – number of studied cases; s/n –seronegative 
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